Antimicrobial therapy for skin infections

Cutis

Volumn 79, Issue 6 SUPPL., 2007, Pages 26-36

  Hirschmann, Jan V ^a,b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ARTICLE; ATOPIC DERMATITIS; BACTERIAL SKIN DISEASE; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; PENICILLIN RESISTANCE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; VARICOSIS; WOUND DRAINAGE;

ANTI-BACTERIAL AGENTS; DERMATITIS, ATOPIC; DRAINAGE; HUMANS; METHICILLIN RESISTANCE; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; VARICOSE ULCER;

EID: 34547528447     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Hirschmann JV. Impetigo: etiology and therapy. In: Remington JS, Swartz MN, eds. Current Clinical Topics in Infectious Diseases. Maiden, Mass: Blackwell Publishing; 2002:42-51.
2. Dagan R, Bar-David Y. Comparison of amoxicillin and clavulanic acid (augmentin) for the treatment of non-bullous impetigo. Am J Dis Child. 1989;143:916-918.
3. Bass JW, Chan DS, Creamer KM, et al. Comparison of oral cephalexin, topical mupirocin and topical bacitracin for treatment of impetigo. Ped Infect Dis J. 1997;16:708-710.
4. Demidovich CW, Wittier RR, Ruff ME, et al. Impetigo, current etiology and comparison of penicillin, erythromycin, and cephalexin therapies. Am J Dis Child. 1990;144:1313-1315.
5. Hirschmann JV. Topical antibiotics in dermatology. Arch Dermatol. 1988;124:1691-1700.
6. Koning S, van Suijlekom-Smit LW, Nouwen JL, et al. Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial. BMJ. 2002;324:203-206.
7. Booth JH, Benrimoj SI. Mupirocin in the treatment of impetigo. Int J Dermatol. 1992;31:1-9.
8. Maddox JS, Ware JC, Dillon HC. The natural history of streptococcal skin infection: prevention with topical antibiotics. J Am Acad Dermatol. 1985;13(2 pt 1): 207-212.
9. Wertheim HF, Melles DC, Vos MC, et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis. 2005;5:751-762.
10. Lipsky BA, Pecoraro RE, Ahroni JH, et al. Immediate and long-term efficacy of systemic antibiotics or eradicating nasal colonization with Staphylococcus aureus. Eur J Clin Microbiol Infect Dis. 1992;11:43-47.
11. Klempner MS, Styrt B. Prevention of recurrent staphy-lococcal skin infections with low-dose oral clindamycin. JAMA. 1988;260:2682-2685.
12. Kyne L, Farrell RJ, Kelly CP. Clostridium difficile. Gastroenterol Clin N Am. 2001;30:753-777.
13. Doebbeling BN, Breneman DL, Neu HC, et al. Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. The Mupirocin Collaborative Study Group. Clin Infect Dis. 1993;17:466-474.
14. Doebbeling BN, Reagan DR, Pfallet MA, et al. Long-term efficacy of intranasal mupirocin ointment, a prospective cohort study of Staphylococcus aureus carriage. Arch Intern Med. 1994;154:1505-1508.
15. Raz R, Miron D, Colodner R, et al. A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection. Arch Intern Med. 1996;156:1109-1112.
16. Chartrier C, Grosshans E. Erysipelas. Int J Dermatol. 1990;29:459-467.
17. Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ. 1999;318:1591-1594.
18. Perl B, Gottehrer NP, Raveh D, et al. Cost-effectiveness of blood cultures for adult patients with cellulitis. Clin Infect Dis. 1999;29:1483-1488.
19. Hook EW, Hooton TM, Horton CA, et al. Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med. 1986;146:295-297.
20. Goldgeier MH. The microbial evaluation of acute cellulitis. Cutis. 1983;31:649-650, 653-654, 656.
21. Sachs MK. The optimum use of needle aspiration in the bacteriologic diagnosis of cellulitis in adults. Arch Intern Med. 1990;150:1907-1912.
22. Duvanel T, Auckengthaler R, Rohner P, et al. Quantitative cultures of biopsy specimens from cutaneous cellulitis. Arch Intern Med. 1989;149:293-296.
23. Newell PM, Norden CW. Value of needle aspiration in bacteriologic diagnosis of cellulitis in adults. J Clin Microbiol. 1988;26:401-404.
24. Lutomski DM, Trott AT, Runyon JM, et al. Microbiology of adult cellulitis. J Fam Pract. 1988;26:45-48.
25. Liles DK, Dall LH. Needle aspiration for diagnosis of cellulitis. Cutis. 1985;36:63-64.
26. Ginsberg MB. Cellulitis: analysis of 101 cases and review of the literature. South Med J. 1981;74:530-533.
27. Kielhofner MA, Brown B, Dall L. Influence of underlying disease process on the utility of cellulitis needle aspirates. Arch Intern Med. 1988;148:2451-2452.
28. Lee PC, Turnidge J, McDonald PJ. Fine-needle aspiration biopsy in diagnosis of soft tissue infections. J Clin Microbiol. 1985;22:80-83.
29. Musher DM, Fainstein V, Young EJ. Treatment of cellulitis with ceforanide. Antimicrob Agents Chemother. 1980;17:254-257.
30. Lebre C, Girard-Pipau F, Roujeau JC, et al. Value of fine-needle aspiration in infectious cellulitis. Arch Dermatol. 1996;132:842-843.
31. Sigurdsson AF, Gudmundsson S. The etiology of bacterial cellulitis as determined by fine-needle aspiration. Scand J Infect Dis. 1989;21:537-542.
32. Bernard P, Bedane C, Mounier M, et al. Streptococcal cause of erysipelas and cellulitis in adults. a microbiologic study using a direct immunofluorescent technique. Arch Dermatol. 1989;125:779-782.
33. Bernard P, Plantin P, Roger H, et al. Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study. Br J Dermatol. 1992;127:155-159.
34. Jorup-Ronstrom C, Britton S, Gavlevik A, et al. The course, costs and complications of oral versus intravenous penicillin therapy of erysipelas. Infection. 1984;12:390-394.
35. Bernard P, Chosidow O, Vaillant L. Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial. BMJ. 2002;325:864-866.
36. Hepburn MJ, Dooley DP, Skidmore PJ, et al. Comparison of short-course (5-days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med. 2004;164:1669-1674.
37. Sachs MK. Cutaneous cellulitis. Arch Dermatol. 1991;127:493-496.
38. Bergkvist PI, Sjobeck K. Antibiotic and prednisolone therapy of erysipelas: a randomized, double blind, placebo-controlled study. Scand J Infect Dis. 1997;29:377-382.
39. Bergkvist PI, Sjobeck K. Relapse of erysipelas following treatment with prednisolone or placebo in addition to antibiotics: a 1-year follow-up. Scand J Infect Dis. 1998;30:206-207.
40. De Godoy JM, De Godoy MF, Valente A, et al. Lymphoscintigraphic evaluation of patients after erysipelas. Lymphology. 2000;33:177-180.
41. Jorup-Ronstrom C, Britton S. Recurrent erysipelas: predisposing factors and costs of prophylaxis. Infection. 1987;2:105-106.
42. Eriksson B, Jorup-Ronstrom C, Karkkonen K, et al. Erysipelas: clinical and bacteriologic spectrum and serologic aspects. Clin Infect Dis. 1996;23:1091-1098.
43. Semel JD, Goldin H. Association of athlete's foot with cellulitis of the lower extremities: diagnostic alue of bacterial cultures of ipsilateral inter-digital space samples. Clin Infect Dis. 1996;23:1162-1164.
44. Sjoblom AC, Eriksson B, Jorup-Ronstrom C, et al. Antibiotic prophylaxis in recurrent erysipelas. Infection. 1993;21:390-393.
45. Kremer M, Zuckerman R, Avraham Z, et al. Long-term antimicrobial therapy in the prevention of recurrent soft-tissue infections. J Infect. 1991;22:37-40.
46. Meislin HW, Lerner SA, Graves MH, et al. Cutaneous abscesses, anaerobic and aerobic bacteriology and outpatient management. Ann Intern Med. 1977;87:145-149.
47. Brook I, Frazier EH. Aerobic and anaerobic bacteriology of wounds and cutaneous abscesses. Arch Surg. 1990;125:1445-1451.
48. Whitehead SM, Leach RD, Eykyn SJ, et al. The aetiology of scrotal sepsis. Br J Surg. 1982;69:729-730.
49. Leach RD, Eykyn SJ, Phillips I, et al. Anaerobic axillary abscess. Br Med J. 1979;2:5-7.
50. Leach RD, Eykyn SJ, Phillips I, et al. Anaerobic subareolar abscess. Lancet. 1979;1:35-37.
51. Whitehead SM, Leach RD, Eykyn SJ, et al. The aetiology of perirectal sepsis. Br J Surg. 1982;69:166-168.
52. Ghoneim AT, McGoldrick J, Blick PW, et al. Aerobic and anaerobic bacteriology of subcutaneous abscesses. Br J Surg. 1981;68:498-500.
53. Edminston CE, Walker AP, Krepel CJ, et al. The nonpuerperal breast infection: aerobic and anaerobic microbial recovery from acute and chronic disease. J Infect Dis. 1990;162:695-699.
54. Whitehead SM, Eykyn SJ, Phillips I. Anaerobic paronychia. Br J Surg. 1981;68:420-422.
55. Fridkin SK, Hageman JC, Morrison M, et al. Methicillinresistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005;352:1436-1444.
56. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S aureus infections among patients in the emergency department. N Engl J Med. 2006;355:666-674.
57. Frazee BW, Lynn J, Charlebois ED, et al. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med. 2005;45:311-320.
58. Rutherford WH, Calderwood JW, Hart D, et al. Anti-biotics in surgical treatment of septic lesions. Lancet. 1970;1:1077-1080.
59. Macfie J, Harvey J. The treatment of acute superficial abscesses: a prospective clinical trial. Br J Surg. 1977;64:264-266.
60. Llera JL, Levy RC. Treatment of cutaneous abscess: a double-blind clinical study. Ann Emerg Med. 1985;14:15-19.
61. Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin- resistant Staphylococcus aureus. Pediatr Infect Dis J. 2004;23:123-127.
62. Paydar KZ, Hansen SL, Charlebois ED, et al. Inappropriate antibiotic use in soft tissue infections. Arch Surg. 2006;141:850-856.
63. Diven DG, Dozier SE, Meyer DJ, et al. Bacteriology of inflamed and uninflamed epidermal inclusion cysts. Arch Dermatol. 1998;134:49-51.
64. Erickson G, Eklund AE, Kallinger LO. The clinical significance of bacterial growth in venous leg ulcers. Scand J Infect Dis. 1984;16:175-180.
65. Alinovi A, Bassissi P, Pini M. Systemic administration of antibiotics in the management of venous ulcers: a randomized clinical trial. J Am Acad Dermatol. 1986;15:186-191.
66. Hansson C, Hoborn J, Moller A, et al. The microbial flora in venous leg ulcers without clinical signs of infection. repeated culture using a validated standardized microbiological technique. Acta Derm Venereol (Stockh). 1995;75:24-30.
67. Gilchrist B, Reed C. The bacteriology of chronic venous ulcers treated with occlusive hydrocolloid dressings. Br J Dermatol. 1989;121:337-344.
68. Pardes JB, Carson PA, Eaglstein WH, et al. Mupirocin treatment of exudative venous ulcers. J Am Acad Dermatol. 1993;29:497-498.
69. Huovinen S, Kotilainen P, Jarvinen H, et al. Comparison of ciprofloxacin or trimethoprim therapy for venous leg ulcers: results of a pilot study. J Am Acad Dermatol. 1994;31:279-281.
70. Ewing CI, Ashcroft C, Gibbs AC, et al. Flucloxacillin in the treatment of atopic dermatitis. Br J Dermatol. 1998;138:1022-1029.
71. Aly R, Maibach HI, Shinefield HR. Microbial flora of atopic dermatitis. Arch Dermatol. 1977;113:780-782.
72. Leyden JJ, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol. 1974;90:525-530.
73. Goodyear HM, Watson PJ, Egan SA, et al. Skin microflora of atopic eczema in first time hospital attenders. Clin Exper Dermatol. 1993;18:300-304.
74. Masenga J, Garbe C, Wagner J, et al. Staphylococcus aureus in atopic dermatitis and in nonatopic dermatitis. Int J Dermatol. 1990;29:579-582.
75. Lever R, Hadley K, Downey D, et al. Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol. 1988;119:189-198.
76. Wachs GN, Maibach HI. Co-operative double-blind trial of an antibiotic/corticoid combination in impetiginized atopic dermatitis. Br J Dermatol. 1976;95:323-328.
77. Breuer K, Haussler S, Kapp A, et al. Staphylococcus aureus: colonizing features and influence of an anti-bacterial treatment in adults with atopic dermatitis. Br J Dermatol. 2002;147:55-61.
78. Nilsson EJ, Henning CG, Magnusson J. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol. 1992;27:29-34.
79. Stalder JF, Fleury M, Sourisse M, et al. Local steroid therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol. 1994;131:536-540.
80. Hjorth N, Schmidt H, Thomsen K. Fusidic acid plus betamethasone in infected or potentially infected eczema. Pharmatherapeutica. 1985;4:126-131.
81. Leyden JJ, Kligman AM. The case for steroid-antibiotic combination. Br J Dermatol. 1977;96:179-187.
82. Gong JQ, Lin L, Lin T, et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol. 2006;155:680-687.
83. Boguniewicz M, Sampson H, Leung SB, et al. Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. J Allergy Clin Immunol. 2001;108:651-652.
84. Hanifin JM, Rogge JL. Staphylococcal infections in patients with atopic dermatitis. Arch Dermatol. 1977;113:1383-1386.